Date:9/29/2010

2009, respectively 8,185,240 5,620,519 Inventory 3,588,824 3,808,289 Advance payments 382,980 1,188,115 Loans receivable 294,600 -- Other current assets 77,283 683,189 Total current assets 39,537,993 23,652,335 Property and equipment, net 14,968,822 9,642,526 Intangibles, net 15,232,286 12,037,483 Total assets $69,739,101 $45,332,344 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses $1,715,781 $1,392,639 Accounts payable - construction related 2,248,849 -- Short-term bank loans 1,473,000 1,399,075 VAT taxes payable 658,312 458,930 Income taxes payable 861,614 490,514 Other taxes payable 19,564 11,890 Dividends payable 72,995 325,417 Other current liabilities 429,135 307,934 Total current liabilities 7,479,250 4,386,399 Total liabilities 7,479,250 4,386,399 Stockholders' equity: Common stock, $0.001 par value, 50,000,000 shares authorized, 27,326,527 and 17,908,912 shares issued and outstanding at June 30, 2010 and 2009, respectively 27,326 17,909 Series A convertible preferred stock, $0.001 par value, 1,360,250 and 7,146,500 shares issued and outstanding at June 30, 2010 and 2009, respectively 1,360 7,147 Additional paid-in capital 29,623,396 19,694,514 Statutory reserve 3,732,883 2,299,807 Treasury stock (111,587) (111,587) Retained earnings 25,687,770 16,486,775 Accumulated other comprehensive income 2,845,076 2,551,380 Total stockholders' equity 61,806,224 40,945,945 Noncontrolling interest 453,627 -- Total equity 62,259,851 40,945,945 Total liabilities and stockholders' equity $69,739,101 $45,322,344 Consolidated Statements of Operations and Comprehensive Income For the Years Ended June 30, 2010 2009 Sales $63,939,684 $42,894,355 Cost of sales 30,594,639 21,516,065 Gross profit 33,345,045 21,378,290 Operating expenses Selling expenses 12,796,881 7,825,939 General and administrative expenses 4,949,179 3,491,804 Research and development 852,848 343,952 Total operating expenses 18,598,908 11,661,695 Income from operatio
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related biology technology :

1. Tianyin Corporate Presentation Updated
2. Tianyin Reports Record Third Quarter 2010 Financial Results
3. Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16
4. Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9
5. Tianyin Pharmaceutical Co., Inc. Expects to Benefit from the Recently Published Guide to Pricing Reform for Medicine and Medical Services
6. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
7. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
8. Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET
9. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
10. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
11. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets